Why unbranded ads don’t work
Patrick Kelly, President of Pfizer US Pharmaceuticals, who testified at the recent FDA public hearing on DTC, announced that Pfizer has allocated a portion...
FDA DTC Hearings Day 2
The second day of the FDA hearings on DTC was essentially more of the same as the first day. There were, however, a few...
FDA DTC Hearings: Snippets from Day 1
I am in Washington, DC attending the FDA public hearing on DTC. I will try to summarize a few of the more interesting presentations...
Patient Level Data for the Pharmaceutical Industry
How Pharma Companies Are Using PLD to Drive Brand Performance
Pharma Marketing Blog a “Must Read”
Last week my quest for blogging stardom got a big boost -- the Wall Street Journal cited Pharma Marketing Blog as a blog insiders should read to stay current!
Sales Rep Assessment: Shoot the Messenger, the Message, or Both?
This article is a review of Metamorph, Inc.'s methodology of using specially trained physicians to assess and validate sales strategy, marketing messages and sales aids of pharmaceutical companies based on real-time calls with reps using a standardised set of data points.
Global Digital Asset Brand Management
There is a need to leverage rich media content across Rx brands and marketing campaigns on a global scale. This article is a review of ClearStory Systems' ActiveMedia, which is an example of a next-generation digital asset management (DAM) solution for managing rich media.
GSK Strikes Back with a Grassroots Campaign
Mike Pucci, Vice President of External Affairs at GlaxoSmithKline, discusses his strategy to get the word out about the good that the pharmaceutical industry is doing.
Predictive Physician Marketing
Now there is a method proven to predict the success of a campaign prior to launch. The ProSigma Detail Model created by TargetRx, a marketing information services company located in Horsham, PA, helps pharmaceutical marketers develop the best detail and detail piece to drive prescribing behavior.
DTC Pros and Cons Presented at FDA Hearing
This article summarizes the main points, both pro and con, made by presenters at recent FDA hearing on DTC and includes commentary from expert members of the Pharms Marketing Roundtable, which met to discuss the issues raised at this hearing.
